|
CA3073384A1
(en)
|
2008-09-05 |
2010-03-11 |
President And Fellows Of Harvard College |
Continuous directed evolution of proteins and nucleic acids
|
|
AU2011265733B2
(en)
*
|
2010-06-14 |
2014-04-17 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of TAL effector and Foki fusion protein
|
|
JP6088438B2
(ja)
|
2010-12-22 |
2017-03-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
連続的定向進化
|
|
EP2732038B1
(en)
|
2011-07-15 |
2018-09-05 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US20150017728A1
(en)
*
|
2011-09-23 |
2015-01-15 |
Iowa State University Research Foundation, Inc |
Monomer architecture of tal nuclease or zinc finger nuclease for dna modification
|
|
WO2013068845A2
(en)
|
2011-11-07 |
2013-05-16 |
The University Of Western Ontario |
Endonuclease for genome editing
|
|
WO2013074999A1
(en)
|
2011-11-16 |
2013-05-23 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
|
US9688997B2
(en)
|
2011-12-29 |
2017-06-27 |
Iowa State University Research Foundation, Inc. |
Genetically modified plants with resistance to Xanthomonas and other bacterial plant pathogens
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
DK3415158T3
(da)
*
|
2012-03-15 |
2021-01-11 |
Cellectis |
Repeat-variable direster til targeting af nukleotider
|
|
WO2013158309A2
(en)
*
|
2012-04-18 |
2013-10-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
CA2871008C
(en)
|
2012-04-23 |
2022-11-22 |
Bayer Cropscience Nv |
Targeted genome engineering in plants
|
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
EP2855666B1
(en)
|
2012-05-25 |
2019-12-04 |
Cellectis |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
EP2855671B1
(en)
*
|
2012-06-05 |
2019-02-20 |
Cellectis |
Transcription activator-like effector (tale) fusion protein
|
|
EP2861737B1
(en)
|
2012-06-19 |
2019-04-17 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
|
US9091827B2
(en)
|
2012-07-09 |
2015-07-28 |
Luxtera, Inc. |
Method and system for grating couplers incorporating perturbed waveguides
|
|
AU2013312838B2
(en)
|
2012-09-04 |
2018-11-29 |
Cellectis |
Multi-chain chimeric antigen receptor and uses thereof
|
|
CN103668470B
(zh)
*
|
2012-09-12 |
2015-07-29 |
上海斯丹赛生物技术有限公司 |
一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
|
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
EP4556564A3
(en)
|
2012-10-23 |
2025-09-03 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
CA2890160A1
(en)
|
2012-10-31 |
2014-05-08 |
Cellectis |
Coupling herbicide resistance with targeted insertion of transgenes in plants
|
|
BR122019025681B1
(pt)
*
|
2012-11-01 |
2023-04-18 |
Factor Bioscience Inc |
Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
|
|
US10415024B2
(en)
|
2012-11-16 |
2019-09-17 |
Poseida Therapeutics, Inc. |
Site-specific enzymes and methods of use
|
|
BR112015011190A2
(pt)
|
2012-11-16 |
2017-10-03 |
Total Marketing Services |
Método de modificação dirigida e célula de alga geneticamente modificada
|
|
WO2014102688A1
(en)
|
2012-12-27 |
2014-07-03 |
Cellectis |
New design matrix for improvement of homology-directed gene targeting
|
|
EP2951295B1
(en)
|
2013-02-01 |
2018-08-01 |
Cellectis |
Tevi chimeric endonucleases and their preferential cleavage sites
|
|
US10676749B2
(en)
|
2013-02-07 |
2020-06-09 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
US20150353885A1
(en)
|
2013-02-21 |
2015-12-10 |
Cellectis |
Method to counter-select cells or organisms by linking loci to nuclease components
|
|
AU2014235794A1
(en)
*
|
2013-03-14 |
2015-10-22 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2981614A1
(en)
|
2013-04-02 |
2016-02-10 |
Bayer CropScience NV |
Targeted genome engineering in eukaryotes
|
|
CN105008536A
(zh)
*
|
2013-04-16 |
2015-10-28 |
深圳华大基因科技服务有限公司 |
分离的寡核苷酸及其用途
|
|
SG11201508805UA
(en)
|
2013-05-13 |
2015-11-27 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
|
JP2016524464A
(ja)
|
2013-05-13 |
2016-08-18 |
セレクティスＣｅｌｌｅｃｔｉｓ |
免疫療法のために高活性ｔ細胞を操作するための方法
|
|
AU2014273089B2
(en)
*
|
2013-05-31 |
2018-02-22 |
Cellectis |
A LAGLIDADG homing endonuclease cleaving the C-C Chemokine Receptor Type-5 (CCR5) gene and uses thereof
|
|
AU2014273091B2
(en)
*
|
2013-05-31 |
2019-12-12 |
Cellectis |
A LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
|
|
EP3008186B1
(en)
*
|
2013-06-14 |
2018-11-28 |
Cellectis |
Methods for non-transgenic genome editing in plants
|
|
AU2014301147B2
(en)
*
|
2013-06-25 |
2020-07-30 |
Cellectis |
Modified diatoms for biofuel production
|
|
FR3008106A1
(fr)
*
|
2013-07-05 |
2015-01-09 |
Agronomique Inst Nat Rech |
Methode d'induction d'une recombinaison meiotique ciblee
|
|
US10782479B2
(en)
|
2013-07-08 |
2020-09-22 |
Luxtera Llc |
Method and system for mode converters for grating couplers
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US10006011B2
(en)
|
2013-08-09 |
2018-06-26 |
Hiroshima University |
Polypeptide containing DNA-binding domain
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
AU2014321215B2
(en)
*
|
2013-09-23 |
2020-07-16 |
Rensselaer Polytechnic Institute |
Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
|
|
US9476884B2
(en)
|
2013-10-04 |
2016-10-25 |
University Of Massachusetts |
Hybridization- independent labeling of repetitive DNA sequence in human chromosomes
|
|
AU2014338910B2
(en)
*
|
2013-10-25 |
2020-12-10 |
Cellectis |
Design of rare-cutting endonucleases for efficient and specific targeting DNA sequences comprising highly repetitive motives
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
|
EP3092049A1
(en)
|
2014-01-08 |
2016-11-16 |
Flodesign Sonics Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
EP3097196B1
(en)
|
2014-01-20 |
2019-09-11 |
President and Fellows of Harvard College |
Negative selection and stringency modulation in continuous evolution systems
|
|
KR102157924B1
(ko)
|
2014-02-14 |
2020-10-26 |
셀렉티스 |
면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들
|
|
RU2752933C2
(ru)
|
2014-03-11 |
2021-08-11 |
Селлектис |
Способ создания т-клеток, пригодных для аллогенной трансплантации
|
|
MX370272B
(es)
|
2014-03-19 |
2019-12-09 |
Cellectis |
Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
|
|
CA2939847C
(en)
|
2014-03-21 |
2023-09-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genome editing without nucleases
|
|
JP2017513472A
(ja)
|
2014-04-11 |
2017-06-01 |
セレクティスＣｅｌｌｅｃｔｉｓ |
アルギニンおよび／またはトリプトファン枯渇微小環境に対して抵抗性を有する免疫細胞を作製するための方法
|
|
JP2017518082A
(ja)
*
|
2014-06-17 |
2017-07-06 |
ポセイダ セラピューティクス， インコーポレイテッド |
ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用
|
|
WO2016016344A1
(en)
|
2014-07-29 |
2016-02-04 |
Cellectis |
Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
|
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
CA2956482A1
(en)
|
2014-07-31 |
2016-02-04 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
|
DK3189073T4
(da)
|
2014-09-04 |
2025-08-18 |
Cellectis |
Trofoblastglykoprotein (5t4, tpbg)-specifikke kimære antigenreceptorer til cancerimmunterapi
|
|
US10920208B2
(en)
|
2014-10-22 |
2021-02-16 |
President And Fellows Of Harvard College |
Evolution of proteases
|
|
CA2973529A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
JP7199809B2
(ja)
|
2015-02-13 |
2023-01-06 |
ファクター バイオサイエンス インコーポレイテッド |
核酸製品及びその投与方法
|
|
US20160244784A1
(en)
*
|
2015-02-15 |
2016-08-25 |
Massachusetts Institute Of Technology |
Population-Hastened Assembly Genetic Engineering
|
|
EP3268388A1
(en)
|
2015-03-11 |
2018-01-17 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
EP4015633A1
(en)
*
|
2015-05-01 |
2022-06-22 |
Precision Biosciences, Inc. |
Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
|
|
US10752670B2
(en)
|
2015-05-20 |
2020-08-25 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
|
JP2018521689A
(ja)
|
2015-06-17 |
2018-08-09 |
ポセイダ セラピューティクス， インコーポレイテッド |
タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
|
|
WO2017001572A1
(en)
|
2015-06-30 |
2017-01-05 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
|
CN104962523B
(zh)
|
2015-08-07 |
2018-05-25 |
苏州大学 |
一种测定非同源末端连接修复活性的方法
|
|
AU2016307050A1
(en)
|
2015-08-11 |
2018-02-15 |
Cellectis |
Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
|
|
SG11201803173VA
(en)
|
2015-10-23 |
2018-05-30 |
Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017079428A1
(en)
|
2015-11-04 |
2017-05-11 |
President And Fellows Of Harvard College |
Site specific germline modification
|
|
WO2017178585A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
WO2017178586A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
US11293033B2
(en)
|
2016-05-18 |
2022-04-05 |
Amyris, Inc. |
Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
|
|
JP6995783B2
(ja)
|
2016-05-26 |
2022-02-04 |
ヌンヘムス、ベスローテン、フェンノートシャップ |
種なし果実を実らせる植物
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
MX2019001956A
(es)
|
2016-08-17 |
2019-09-04 |
Monsanto Technology Llc |
Metodos y composiciones para plantas de estatura corta a traves de la manipulacion del metabolismo de giberelina para aumentar el rendimiento cosechable.
|
|
EP3500585A4
(en)
|
2016-08-17 |
2020-04-01 |
Factor Bioscience Inc. |
NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
ES2811500T3
(es)
|
2016-10-04 |
2021-03-12 |
Prec Biosciences Inc |
Dominios coestimuladores para su uso en células genéticamente modificadas
|
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
|
CN110168102A
(zh)
*
|
2016-11-15 |
2019-08-23 |
基因组影像公司 |
利用分子梳理监测经修饰的核酸酶诱导的基因编辑事件的方法
|
|
KR20240172763A
(ko)
|
2016-12-14 |
2024-12-10 |
리간달 인코포레이티드 |
핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법
|
|
WO2018115189A1
(en)
|
2016-12-21 |
2018-06-28 |
Cellectis |
Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
US20200010519A1
(en)
|
2017-03-10 |
2020-01-09 |
Institut National De La Sante Et De La Recherche Medicale(Inserm) |
Nuclease fusions for enhancing genome editing by homology-directed transgene integration
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
JP6901293B2
(ja)
*
|
2017-03-15 |
2021-07-14 |
株式会社三共 |
遊技用装置
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
WO2018178377A1
(en)
|
2017-03-31 |
2018-10-04 |
Cellectis Sa |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
|
JP7170666B2
(ja)
|
2017-05-08 |
2022-11-14 |
プレシジョン バイオサイエンシズ，インク． |
操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
JP7191042B2
(ja)
|
2017-05-25 |
2022-12-16 |
２セブンティ バイオ インコーポレイテッド |
Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法
|
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
US11447809B2
(en)
|
2017-07-06 |
2022-09-20 |
President And Fellows Of Harvard College |
Evolution of tRNA synthetases
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
AU2018321405A1
(en)
|
2017-08-25 |
2020-03-05 |
Ipsen Biopharm Ltd. |
Evolution of BoNT peptidases
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
US11624130B2
(en)
|
2017-09-18 |
2023-04-11 |
President And Fellows Of Harvard College |
Continuous evolution for stabilized proteins
|
|
WO2019060631A1
(en)
*
|
2017-09-20 |
2019-03-28 |
Helix Nanotechnologies, Inc. |
EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE
|
|
EP3692057B9
(en)
|
2017-10-03 |
2023-10-04 |
Precision BioSciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
|
AU2018352592C1
(en)
|
2017-10-16 |
2025-09-25 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
|
MX2020004967A
(es)
|
2017-11-17 |
2020-08-27 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
|
|
JP2021507561A
(ja)
|
2017-12-14 |
2021-02-22 |
フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． |
音響トランスデューサドライバ及びコントローラ
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
EP3501268B1
(en)
|
2017-12-22 |
2021-09-15 |
KWS SAAT SE & Co. KGaA |
Regeneration of plants in the presence of histone deacetylase inhibitors
|
|
EP3508581A1
(en)
|
2018-01-03 |
2019-07-10 |
Kws Saat Se |
Regeneration of genetically modified plants
|
|
AU2019207409B2
(en)
|
2018-01-12 |
2023-02-23 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
|
AU2019216269B2
(en)
|
2018-01-30 |
2025-05-01 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
|
|
CA3090007A1
(en)
|
2018-02-15 |
2019-08-22 |
Monsanto Technology Llc |
Improved methods for hybrid corn seed production
|
|
CA3089883A1
(en)
|
2018-02-15 |
2019-08-22 |
Monsanto Technology Llc |
Compositions and methods for improving crop yields through trait stacking
|
|
EP3545756A1
(en)
|
2018-03-28 |
2019-10-02 |
KWS SAAT SE & Co. KGaA |
Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
US20210015869A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3099102C
(en)
|
2018-05-02 |
2024-05-14 |
Cellectis |
Engineering wheat with increased dietary fiber
|
|
HRP20251258T1
(hr)
|
2018-05-09 |
2025-12-05 |
KWS SAAT SE & Co. KGaA |
Gen za rezistenciju na patogen roda heterodera
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
AU2019287720B2
(en)
|
2018-06-14 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
CD79A chimeric antigen receptors
|
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
|
WO2019238911A1
(en)
|
2018-06-15 |
2019-12-19 |
KWS SAAT SE & Co. KGaA |
Methods for improving genome engineering and regeneration in plant ii
|
|
BR112020025349A2
(pt)
|
2018-06-15 |
2021-03-09 |
KWS SAAT SE & Co. KGaA |
Métodos para melhorar a engenharia e regeneração do genoma em planta
|
|
WO2019238832A1
(en)
|
2018-06-15 |
2019-12-19 |
Nunhems B.V. |
Seedless watermelon plants comprising modifications in an abc transporter gene
|
|
WO2019238908A1
(en)
|
2018-06-15 |
2019-12-19 |
KWS SAAT SE & Co. KGaA |
Methods for enhancing genome engineering efficiency
|
|
US20210268028A1
(en)
|
2018-07-02 |
2021-09-02 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
|
EP3623379A1
(en)
|
2018-09-11 |
2020-03-18 |
KWS SAAT SE & Co. KGaA |
Beet necrotic yellow vein virus (bnyvv)-resistance modifying gene
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
ES3021682T3
(en)
|
2018-11-05 |
2025-05-27 |
Iovance Biotherapeutics Inc |
Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
|
|
JP2022506586A
(ja)
|
2018-11-05 |
2022-01-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用
|
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
|
AU2019375416A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive T-cells
|
|
US12274205B2
(en)
|
2018-12-12 |
2025-04-15 |
Monsanto Technology Llc |
Delayed harvest of short stature corn plants
|
|
US20220193131A1
(en)
|
2018-12-19 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
|
|
US20220090047A1
(en)
|
2018-12-21 |
2022-03-24 |
Precision Biosciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
CN113490747B
(zh)
|
2019-01-29 |
2024-12-31 |
华威大学 |
用于提高基因组工程化效率的方法
|
|
BR112021016875A2
(pt)
|
2019-03-01 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Processo para expansão de linfócitos de sangue periférico
|
|
EP3708651A1
(en)
|
2019-03-12 |
2020-09-16 |
KWS SAAT SE & Co. KGaA |
Improving plant regeneration
|
|
GB2601617B
(en)
|
2019-03-19 |
2024-02-21 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
|
WO2020198264A1
(en)
*
|
2019-03-26 |
2020-10-01 |
Encodia, Inc. |
Modified cleavases, uses thereof and related kits
|
|
US11427814B2
(en)
|
2019-03-26 |
2022-08-30 |
Encodia, Inc. |
Modified cleavases, uses thereof and related kits
|
|
KR20240122580A
(ko)
|
2019-04-03 |
2024-08-12 |
프리시젼 바이오사이언시스 인코포레이티드 |
마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
|
|
CA3136265A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
|
EP3966334A1
(en)
|
2019-05-10 |
2022-03-16 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP3757219A1
(en)
|
2019-06-28 |
2020-12-30 |
KWS SAAT SE & Co. KGaA |
Enhanced plant regeneration and transformation by using grf1 booster gene
|
|
CN114450265B
(zh)
|
2019-07-03 |
2024-12-24 |
菲克特生物科学股份有限公司 |
阳离子脂质及其用途
|
|
EP4004216A1
(en)
|
2019-07-25 |
2022-06-01 |
Precision BioSciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
CA3148179A1
(en)
|
2019-08-20 |
2021-02-25 |
Bruce J. Mccreedy Jr. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2020336302A1
(en)
|
2019-08-23 |
2022-03-03 |
Sana Biotechnology, Inc. |
CD24 expressing cells and uses thereof
|
|
AU2020344905A1
(en)
|
2019-09-12 |
2022-04-28 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
|
WO2021069387A1
(en)
|
2019-10-07 |
2021-04-15 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20220411479A1
(en)
|
2019-10-30 |
2022-12-29 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
|
BR112022009067A2
(pt)
|
2019-11-12 |
2022-08-09 |
Kws Saat Se & Co Kgaa |
Gene para resistência a um patógeno do gênero heterodera
|
|
AU2020396138A1
(en)
|
2019-12-03 |
2022-06-16 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
|
CA3160096A1
(en)
|
2019-12-06 |
2021-06-10 |
Bruce J. Mccreedy Jr. |
Methods for cancer immunotherapy
|
|
JP7749561B2
(ja)
|
2019-12-11 |
2025-10-06 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
|
|
CA3164591A1
(en)
|
2020-01-13 |
2021-07-22 |
William Dowdle |
Modification of blood type antigens
|
|
CN115298314A
(zh)
|
2020-01-17 |
2022-11-04 |
萨那生物技术股份有限公司 |
基因表达调控的安全开关
|
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
|
CA3169128A1
(en)
|
2020-02-28 |
2021-09-02 |
Ling MENG |
Immature inflorescence meristem editing
|
|
BR112022019060A2
(pt)
|
2020-03-25 |
2022-11-29 |
Sana Biotechnology Inc |
Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
|
|
US20230263121A1
(en)
|
2020-03-31 |
2023-08-24 |
Elo Life Systems |
Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
|
|
JP2023523855A
(ja)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
WO2021231549A2
(en)
*
|
2020-05-12 |
2021-11-18 |
Factor Bioscience Inc. |
Engineered gene-editing proteins
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
WO2022036150A1
(en)
|
2020-08-13 |
2022-02-17 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
EP4232461A1
(en)
|
2020-10-23 |
2023-08-30 |
ELO Life Systems, Inc. |
Methods for producing vanilla plants with improved flavor and agronomic production
|
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
US20240299539A1
(en)
|
2020-12-17 |
2024-09-12 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
EP4019638A1
(en)
|
2020-12-22 |
2022-06-29 |
KWS SAAT SE & Co. KGaA |
Promoting regeneration and transformation in beta vulgaris
|
|
EP4019639A1
(en)
|
2020-12-22 |
2022-06-29 |
KWS SAAT SE & Co. KGaA |
Promoting regeneration and transformation in beta vulgaris
|
|
KR20230137900A
(ko)
|
2020-12-31 |
2023-10-05 |
사나 바이오테크놀로지, 인크. |
Car-t 활성을 조정하기 위한 방법 및 조성물
|
|
US20250127811A1
(en)
|
2021-01-28 |
2025-04-24 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
|
EP4284919A1
(en)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
|
|
CN118019546A
(zh)
|
2021-03-23 |
2024-05-10 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞的cish基因编辑及其在免疫疗法中的用途
|
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
|
WO2022226316A1
(en)
|
2021-04-22 |
2022-10-27 |
Precision Biosciences, Inc. |
Compositions and methods for generating male sterile plants
|
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
US20240316198A1
(en)
|
2021-07-14 |
2024-09-26 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
US20240365776A1
(en)
|
2021-07-22 |
2024-11-07 |
Iovance Biotherapeutics, Inc |
Method for cryopreservation of solid tumor fragments
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
EP4384189A1
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
KR20240109615A
(ko)
|
2021-09-09 |
2024-07-11 |
이오반스 바이오테라퓨틱스, 인크. |
Pd-1 talen 녹다운을 사용한 til 생성물의 생성 방법
|
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
|
EP4419111A1
(en)
|
2021-10-19 |
2024-08-28 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
|
JP2024541911A
(ja)
|
2021-10-27 |
2024-11-13 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
患者特異的免疫療法のための細胞の製造を調整するためのシステム及び方法
|
|
CN113980141B
(zh)
*
|
2021-10-27 |
2022-11-29 |
湖北大学 |
基于大肠杆菌素e家族dna酶的蛋白质复合物及其在人工蛋白支架中的应用
|
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023086847A1
(en)
|
2021-11-10 |
2023-05-19 |
Encodia, Inc. |
Methods for barcoding macromolecules in individual cells
|
|
US20250009800A1
(en)
|
2021-11-16 |
2025-01-09 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
MX2024006051A
(es)
|
2021-11-23 |
2024-06-26 |
Cellectis Sa |
Nuevos andamios de proteinas tale con relaciones de actividad en objetivo/fuera de objetivo mejoradas.
|
|
EP4460334A1
(en)
|
2022-01-07 |
2024-11-13 |
Precision BioSciences, Inc. |
Optimized polynucleotides for protein expression
|
|
CA3243419A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
CYTOKINE-ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTE COMPOSITIONS AND PROCESSES
|
|
KR20240155390A
(ko)
|
2022-02-17 |
2024-10-28 |
사나 바이오테크놀로지, 인크. |
조작된 cd47 단백질 및 이의 용도
|
|
US20250101382A1
(en)
|
2022-03-11 |
2025-03-27 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
CA3251533A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
|
|
CA3267168A1
(en)
|
2022-09-09 |
2024-03-14 |
Laurent Poirot |
PROCESSES FOR GENERING TIL PRODUCTS USING DOUBLE INACTIVATION OF TALEN PD-1/TIGIT
|
|
WO2024055018A1
(en)
|
2022-09-09 |
2024-03-14 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
EP4605524A1
(en)
|
2022-10-20 |
2025-08-27 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
|
WO2024097315A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Cell therapy products and methods for producing same
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP4612277A1
(en)
|
2022-11-04 |
2025-09-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024216116A1
(en)
|
2023-04-14 |
2024-10-17 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
WO2024216118A1
(en)
|
2023-04-14 |
2024-10-17 |
Precision Biosciences, Inc. |
Muscle-specific expression cassettes
|
|
AU2024264889A1
(en)
|
2023-05-03 |
2025-11-13 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
CN117344048A
(zh)
*
|
2023-09-28 |
2024-01-05 |
江苏省农业科学院 |
检测无毒基因Avr-Pik的RPA-LFD引物探针组、试剂盒及其应用
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
CN117821413B
(zh)
*
|
2023-12-15 |
2024-12-27 |
湖北大学 |
一种高进行性Pfu DNA聚合酶及其制备方法和应用
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025181336A1
(en)
|
2024-03-01 |
2025-09-04 |
Cellectis Sa |
Compositions and methods for hbb-editing in hspc
|
|
WO2025212519A1
(en)
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|